iboctadekin (SB-485232) / GSK - LARVOL DELTA

A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian T... (clinicaltrials.gov) - P1; N=15; Completed; Sponsor: Abramson Cancer Center of the University of Pennsylvania; Recruiting -> Completed ; Trial primary completion date: Sep 2021 ->Jun 2015

Trial completion • Trial primary completion date • Biosimilar • Oncology • Ovarian Cancer